Control of hepatocellular carcinoma through Hepatitis B vaccination in areas of high endemicity: Perspectives for global liver cancer prevention

Cancer Letters

Volumn 286, Issue 1, 2009, Pages 15-21

  Plymoth, Amelie ^a   Viviani, Simonetta ^a,b   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b Meningitis Vaccine Project   (France)

Author keywords

Field efficacy trials; Hepatitis B vaccination; Hepatocellular carcinoma; Vaccination programmes

Indexed keywords

AFLATOXIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

AGE DISTRIBUTION; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; ENDEMIC DISEASE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HEPATITIS B; HUMAN; INFECTION CONTROL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT SURVEY;

HEPATITIS B VIRUS;

EID: 70350768992     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.08.024     Document Type: Review

References (56)

1. WHO. Hepatitis B vaccines. Wkly. Epidemiol. Rec. 79 (2004) 255-263
2. Shepard C.W., Simard E.P., Finelli L., Fiore A.E., and Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28 (2006) 112-125
3. Lin D.B., Wang H.M., Lee Y.L., Ling U.P., Changlai S.P., and Chen C.J. Immune status in preschool children born after mass hepatitis B vaccination program in Taiwan. Vaccine 16 (1998) 1683-1687
4. Sung J.L., Chen D.S., Lai M.Y., Wang T.H., Wang C.Y., Yu J.Y., and Lee C.Y. Hepatitis B e antigen and antibody in asymptomatic Chinese with hepatitis B surface antigenemia in Taiwan. Gastroenterol. Jpn. 17 (1982) 341-346
5. Whittle H.C., Bradley A.K., McLauchlan K., Ajdukiewicz A.B., Howard C.R., Zuckerman A.J., and McGregor I.A. Hepatitis B virus infection in two Gambian villages. Lancet 1 (1983) 1203-1206
6. Kane M.A. Status of hepatitis B immunization programmes in 1998. Vaccine 16 Suppl. (1998) S104-S108
7. Beasley R.P., Hwang L.Y., Lin C.C., and Chien C.S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 2 (1981) 1129-1133
8. Kirk G.D., Lesi O.A., Mendy M., Akano A.O., Sam O., Goedert J.J., Hainaut P., Hall A.J., Whittle H., and Montesano R. The Gambia liver cancer study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39 (2004) 211-219
9. Ryder R.W., Whittle H.C., Sanneh A.B., Ajdukiewicz A.B., Tulloch S., and Yvonnet B. Persistent hepatitis B virus infection and hepatoma in The Gambia, west Africa. A case-control study of 140 adults and their 603 family contacts. Am. J. Epidemiol. 136 (1992) 1122-1131
10. McMahon B.J. Skriv ut: natural history of chronic hepatitis B - clinical implications. Medscape J. Med. 10 (2008) 91
11. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118 (2006) 3030-3044
12. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
13. Coursaget P., Yvonnet B., Chotard J., Vincelot P., Sarr M., Diouf C., Chiron J.P., and Diop-Mar I. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J. Med. Virol. 22 (1987) 1-5
14. Ekra D., Herbinger K.H., Konate S., Leblond A., Fretz C., Cilote V., Douai C., Da Silva A., Gessner B.D., and Chauvin P. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Cote d'Ivoire. Vaccine 26 (2008) 2753-2761
15. Whittle H., Inskip H., Bradley A.K., McLaughlan K., Shenton F., Lamb W., Eccles J., Baker B.A., and Hall A.J. The pattern of childhood hepatitis B infection in two Gambian villages. J. Infect. Dis. 161 (1990) 1112-1115
16. Stevens C.E., Beasley R.P., Tsui J., and Lee W.C. Vertical transmission of hepatitis B antigen in Taiwan. N. Engl. J. Med. 292 (1975) 771-774
17. Lin H.H., Wang L.Y., Hu C.T., Huang S.C., Huang L.C., Lin S.S., Chiang Y.M., Liu T.T., and Chen C.L. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J. Med. Virol. 69 (2003) 471-474
18. Leuschner I., Harms D., and Schmidt D. The association of hepatocellular carcinoma in childhood with hepatitis B virus infection. Cancer 62 (1988) 2363-2369
19. Lee C.L., and Ko Y.C. Survival and distribution pattern of childhood liver cancer in Taiwan. Eur. J. Cancer 34 (1998) 2064-2067
20. Bah E., Hall A.J., and Inskip H.M. The first 2 years of the Gambian National Cancer Registry. Br. J. Cancer 62 (1990) 647-650
21. J. Ferlay, F. Bray, P. Pisani, D. Parkin, GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase No. 5 (2004).
22. Ni Y.H., Chang M.H., Hsu H.Y., Hsu H.C., Chen C.C., Chen W.J., and Lee C.Y. Hepatocellular carcinoma in childhood. Clinical manifestations and prognosis. Cancer 68 (1991) 1737-1741
23. Fung S.K., and Lok A.S. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection?. Hepatology 40 (2004) 790-792
24. Beasley R.P., Hwang L.Y., Lee G.C., Lan C.C., Roan C.H., Huang F.Y., and Chen C.L. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2 (1983) 1099-1102
25. Chen D.S., Hsu N.H., Sung J.L., Hsu T.C., Hsu S.T., Kuo Y.T., Lo K.J., and Shih Y.T. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 257 (1987) 2597-2603
26. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., and Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N. Engl. J. Med. 336 (1997) 1855-1859
27. Ni Y.H., Chang M.H., Huang L.M., Chen H.L., Hsu H.Y., Chiu T.Y., Tsai K.S., and Chen D.S. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann. Intern. Med. 135 (2001) 796-800
28. Chang M.H. Hepatitis B vaccination and control of hepatitis B-related liver disease. J. Pediatr. Gastroenterol. Nutr. 31 (2000) 112-117
29. Chongsrisawat V., Yoocharoen P., Theamboonlers A., Tharmaphornpilas P., Warinsathien P., Sinlaparatsamee S., Paupunwatana S., Chaiear K., Khwanjaipanich S., and Poovorawan Y. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop. Med. Int. Health 11 (2006) 1496-1502
30. Jutavijittum P., Jiviriyawat Y., Yousukh A., Hayashi S., and Toriyama K. Evaluation of a hepatitis B vaccination program in Chiang Mai, Thailand. Southeast Asian J. Trop. Med. Public Health 36 (2005) 207-212
31. Coursaget P., Leboulleux D., Soumare M., le Cann P., Yvonnet B., Chiron J.P., Coll-Seck A.M., and Diop-Mar I. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J. Hepatol. 21 (1994) 250-254
32. Maupas P., Chiron J.P., Barin F., Coursaget P., Goudeau A., Perrin J., Denis F., and Mar I.D. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet 1 (1981) 289-292
33. Centers for Disease Control and Prevention. Progress in hepatitis B prevention through universal infant vaccination - China, 1997-2006. MMWR Morb. Mortal Wkly. Rep. 56 (2007) 441-445
34. Harpaz R., McMahon B.J., Margolis H.S., Shapiro C.N., Havron D., Carpenter G., Bulkow L.R., and Wainwright R.B. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J. Infect. Dis. 181 (2000) 413-418
35. Hino K., Katoh Y., Vardas E., Sim J., Okita K., and Carman W.F. The effect of introduction of universal childhood hepatitis B immunization in South Africa on the prevalence of serologically negative hepatitis B virus infection and the selection of immune escape variants. Vaccine 19 (2001) 3912-3918
36. Livingston S.E., Simonetti J.P., McMahon B.J., Bulkow L.R., Hurlburt K.J., Homan C.E., Snowball M.M., Cagle H.H., Williams J.L., and Chulanov V.P. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J. Infect. Dis. 195 (2007) 5-11
37. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., and Bell B.P. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 120 (2007) e373-381
38. Poovorawan Y., Theamboonlers A., Vimolket T., Sinlaparatsamee S., Chaiear K., Siraprapasiri T., Khwanjaipanich S., Owatanapanich S., Hirsch P., and Chunsuttiwat S. Impact of hepatitis B immunisation as part of the EPI. Vaccine 19 (2000) 943-949
39. Aspinall S. Effectiveness of a low-cost hepatitis B vaccine in the South African EPI programme: field trial results. Epidemiol. Comments 22 (1995) 8-10
40. Tsebe K.V., Burnett R.J., Hlungwani N.P., Sibara M.M., Venter P.A., and Mphahlele M.J. The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 19 (2001) 3919-3926
41. Sun Z., Zhu Y., Stjernsward J., Hilleman M., Collins R., Zhen Y., Hsia C.C., Lu J., Huang F., Ni Z., et al. Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. Cancer Detect. Prev. 15 (1991) 313-318
42. Hall A., Inskip H., Loik F., et al. The Gambia hepatitis intervention study. The Gambia hepatitis study group. Cancer Res. 47 (1987) 5782-5787
43. Whittle H., Jaffar S., Wansbrough M., Mendy M., Dumpis U., Collinson A., and Hall A. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325 (2002) 569
44. Hall A., Inskip H., Loik F., et al. Hepatitis B vaccine in the expanded programme of immunisation: The Gambian experience. The Gambia hepatitis study group. Lancet 1 (1989) 1057-1059
45. Jack A.D., Hall A.J., Maine N., Mendy M., and Whittle H.C. What level of hepatitis B antibody is protective?. J. Infect. Dis. 179 (1999) 489-492
46. Fortuin M., Chotard J., Jack A.D., Maine N.P., Mendy M., Hall A.J., Inskip H.M., George M.O., and Whittle H.C. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation. Lancet 341 (1993) 1129-1131
47. Viviani S., Jack A., Hall A.J., Maine N., Mendy M., Montesano R., and Whittle H.C. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17 (1999) 2946-2950
48. van der Sande M.A., Waight P.A., Mendy M., Zaman S., Kaye S., Sam O., Kahn A., Jeffries D., Akum A.A., Hall A.J., Bah E., McConkey S.J., Hainaut P., and Whittle H.C. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2 (2007) e753
49. Viviani S., Carrieri P., Bah E., Hall A.J., Kirk G.D., Mendy M., Montesano R., Plymoth A., Sam O., Van der Sande M., Whittle H., and Hainaut P. 20 Years into the Gambia hepatitis intervention study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol. Biomar. Prev. 17 (2008) 3216-3223
50. Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin. Drug Saf. 2 (2003) 225-231
51. van der Sande M.A., Waight P., Mendy M., Rayco-Solon P., Hutt P., Fulford T., Doherty C., McConkey S.J., Jeffries D., Hall A.J., and Whittle H.C. Long-term protection against carriage of hepatitis B virus after infant vaccination. J. Infect. Dis. 193 (2006) 1528-1535
52. Poovorawan Y., Sanpavat S., Chumdermpadetsuk S., and Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch. Dis. Child Fetal Neonatal Ed. 77 (1997) F47-51
53. Lee C., Gong Y., Brok J., Boxall E.H., and Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 332 (2006) 328-336 (Epub 2006 January, 2027)
54. WHO. Meeting of the immunization strategic advisory group of experts, November 2008 - conclusions and recommendations. Wkly. Epidemiol. Rec. 84 (2009) 1-16
55. Chang M.H., Shau W.Y., Chen C.J., Wu T.C., Kong M.S., Liang D.C., Hsu H.M., Chen H.L., Hsu H.Y., and Chen D.S. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 284 (2000) 3040-3042
56. Burnett R.J., Francois G., Kew M.C., Leroux-Roels G., Meheus A., Hoosen A.A., and Mphahlele M.J. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int. 25 (2005) 201-213